Boston Scientific (NYSE:BSX – Get Free Report) had its target price dropped by research analysts at Robert W. Baird from $86.00 to $78.00 in a research report issued to clients and investors on Thursday, MarketBeat.com reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. Robert W. Baird’s price target would indicate a potential upside of 25.79% from the stock’s current price.
BSX has been the subject of several other research reports. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. The Goldman Sachs Group lowered their target price on shares of Boston Scientific from $87.00 to $84.00 and set a “buy” rating for the company in a research note on Wednesday. Wells Fargo & Company lowered their target price on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. TD Cowen lowered their target price on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Finally, Citigroup lowered their target price on shares of Boston Scientific from $94.00 to $87.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $93.91.
Check Out Our Latest Research Report on BSX
Boston Scientific Stock Down 5.6%
Boston Scientific (NYSE:BSX – Get Free Report) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.68%. The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the previous year, the firm earned $0.75 earnings per share. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts predict that Boston Scientific will post 3.37 EPS for the current year.
Insider Activity
In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.34% of the company’s stock.
Hedge Funds Weigh In On Boston Scientific
Hedge funds and other institutional investors have recently modified their holdings of the company. Financial Consulate Inc. acquired a new position in shares of Boston Scientific during the third quarter valued at $25,000. Murphy & Mullick Capital Management Corp boosted its holdings in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 170 shares during the period. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the second quarter valued at $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific in the fourth quarter worth about $26,000. Finally, Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific in the fourth quarter worth about $26,000. Institutional investors and hedge funds own 89.07% of the company’s stock.
More Boston Scientific News
Here are the key news stories impacting Boston Scientific this week:
- Positive Sentiment: Q1 results beat consensus — revenue grew ~11.6% and EPS topped estimates, showing underlying demand and execution that underpinned an initial share pop after the report. Boston Scientific Corporation (NYSE:BSX) Q1 2026 Earnings Call Transcript
- Positive Sentiment: Unusual call-option activity — heavy call buying was reported around the earnings period, indicating some traders are positioning for a rebound or event-driven upside. Traders Purchase High Volume of Boston Scientific Call Options (NYSE:BSX)
- Neutral Sentiment: Analyst views are mixed and the investment story is being reset — several coverage teams trimmed fair-value estimates and split between seeing a buy opportunity versus emphasizing execution risk. This creates divergence in short‑to‑medium term expectations. How The Investment Story Is Resetting For Boston Scientific (BSX) After Recent Analyst Shifts
- Negative Sentiment: Company trimmed 2026 profit and revenue outlook — management lowered full‑year guidance (Q2 trough flagged), which directly reduced near‑term earnings visibility and is the primary driver of the pullback. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
- Negative Sentiment: Analysts slashed price targets after Q1/guidance — multiple firms trimmed targets (Truist, Baird, Needham, others), which amplifies selling pressure and reduces near‑term analyst support. Boston Scientific Analysts Slash Their Forecasts After Q1 Earnings
- Negative Sentiment: Multiple securities‑class action notices and law‑firm solicitations — several firms are soliciting lead‑plaintiff candidates tied to a July 2025–Feb 2026 class period, increasing legal risk and potential headline volatility. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- Negative Sentiment: Downgrades and new 52‑week low headlines — coverage noting downgrades and a 52‑week low contributes to technical selling and stops being hit. Boston Scientific (NYSE:BSX) Hits New 52-Week Low After Analyst Downgrade
Boston Scientific Company Profile
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
See Also
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
